🟢 MetaVia is trading 5% up in pre-market with no confirmed company-specific catalyst

MetaVia is trading at $1.23, up 5.13%, with no confirmed company-specific announcement explaining the pre-market gain as of November 3.

• Coverage published November 2 reported approximately $700,000 in payments due to Dong-A ST remained unpaid as of August 6; MetaVia was adjusting payment timing while prioritizing trials. This is not a confirmed catalyst.
• MetaVia is scheduled to present Phase 1 DA-1726 data November 4, but available reporting does not link the event to the move.